Ocular Therapeutix: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Ocular Therapeutix (NASDAQ:OCUL) reported Q4 earnings with a miss on estimated earnings by -17.0%, posting an EPS of $-0.35 against an estimate of $-0.3. Revenue increased by $726 thousand from the same period last year. Despite beating EPS estimates in Q3 2023, the company's share price dropped by 13.0% the following day.
March 11, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ocular Therapeutix reported a Q4 earnings miss with an EPS of $-0.35, below the estimated $-0.3, but showed an increase in revenue by $726 thousand YOY.
Given the earnings miss and the historical context of a 13.0% drop in share price following a previous earnings beat, it's likely that OCUL's share price may experience short-term negative pressure. The increase in revenue may provide some buffer, but the missed EPS estimate is a significant factor for short-term investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100